Duration of ovulation suppression with subcutaneous silicone implants containing norgestomet in Bos indicus heifers and cows

Polydimethylsiloxane Organic-Inorganic Composite Drug Reservoir with Gliclazide

A novel organic-inorganic gliclazide-loaded composite bead was developed by an ionic gelation process using acidified CaCl2, chitosan and tetraethylorthosilicate (TEOS) as a crosslinker. The beads were manufactured by crosslinking an inorganic silicone elastomer (-OH terminated polydimethylsiloxane, PDMS) with TEOS at different ratios before grafting onto an organic backbone (Na-alginate) using a 32 factorial experimental design. Gliclazide's encapsulation efficiency (EE%) and drug release over 8 h (% DR 8 h) were set as dependent responses for the optimisation of a pharmaceutical formula (herein referred to as 'G op') by response surface methodology. EE % and %DR 8 h of G op were 93.48% ± 0.19 and 70.29% ± 0.18, respectively. G op exhibited a controlled release of gliclazide that follows the Korsmeyer-Peppas kinetic model (R2 = 0.95) with super case II transport and pH-dependent swelling behaviour. In vitro testing of G op showed 92.17% ± 1.18 cell viability upon testing on C2C12 myoblasts, indicating the compatibility of this novel biomaterial platform with skeletal muscle drug delivery.

Effect of indomethacin on embryo implantation and histomorphology of uterus, ovary, kidney, and liver of rats

Background

This study aimed to determine the effects of Indomethacin (IMC) treatment on embryo implantation and histomorphology of uterus, ovary, and other vital organs and its effective dosage in establishing embryo implantation dysfunction model in Sprague-Dawley (SD) rats.

Materials and Methods

The experiments were performed on 24 (6 × 4 groups) adult female SD rats aged 12 weeks old. G1 was the control group and received a normal diet with normal saline. However, on pregnancy days 3 (Pd3) and 4 (Pd4), G2, G3, and G4 were given normal saline and subcutaneously administered IMC twice daily at different doses of 4.33, 4.66 and 5.00 mg/kg body weight, respectively. The rats were euthanized on day 8 of pregnancy (Pd8). The uterus was excised and examined for signs of pregnancy, followed by tissue samples from liver, kidney, and ovary (for histomorphological examination using haematoxylin and eosin stain).

Results

All IMC treatment doses disrupted the implantation process and caused a significant reduction in embryo development. Analysis for histopathological changes revealed that IMC doses above 4.33 mg/kg body weight caused more adverse reproductive health effects in rats. Vasoconstriction and micro vascularization were detected in the liver, while degenerative Bowman's capsules and inflammatory cells were observed in kidney sections from IMC-treated rats.

Conclusion

IMC therapy interfered with implantation and embryo development in rats, resulting in significant uterine vasoconstriction and atrophy, 4.33 mg/kg bwt dose appeared to be optimum to establish embryo implantation dysfunction in SD rats.

Effect of treatment of Bos indicus heifers with progesterone 0, 3 and 6 days after follicular aspiration on follicular dynamics and the timing of oestrus and ovulation

Synchronisation of wave emergence is used to synchronise oestrus in cattle. The aim of this study was to determine if treatment with high concentrations of progesterone in Bos indicus heifers for 3 days would synchronise new wave emergence when treatment commenced at early, mid and late stages of follicular development. Heifers were treated with a sc silicone implant containing norgestomet from Days -7 to 9 and cloprostenol (IM) on Days -7 and -2. All follicles > 4 mm in diameter were removed by transvaginal follicular aspiration either on Days 0 (Experiment 1), 3 (Experiment 2) or 6 (Experiment 3). From Days 6 to 9 every heifer was treated with two intravaginal progesterone releasing inserts that each contained either no progesterone (Control, n = 8/experiment) or 3.12 g of progesterone (n = 8/experiment). Ovarian follicular development was monitored at least once daily following aspiration until oestrus and ovulation. In each experiment, treatment with progesterone significantly increased concentrations of progesterone in plasma from Days 6 to 9 compared to Control heifers. It also significantly delayed the day of emergence of the ovulatory follicle (1.6 ± 0.6 vs 8.6 ± 0.3; 4.1 ± 0.1 vs 8.6 ± 0.2; 7.0 ± 0.0 vs 9.3 ± 0.4, for Control vs progesterone treated heifers, respectively in Experiments 1 to 3) and the interval from implant removal to oestrus and ovulation. In conclusion, treatment with high concentrations of progesterone can synchronise wave emergence in Bos indicus heifers when administered at early, mid and late stages of follicular development.